Skip to main content
SpringerLink
Log in

Biocontainment design considerations for biopharmaceutical facilities

  • Biocontainment Design Issues
  • Published:
Journal of Industrial Microbiology

Summary

This article highlights biocontainment design considerations for biopharmaceutical manufacturing facilities. The major focus of this report is on industry's use and interpretation of the regulations with specific design recommendations for a Biosafety Level 2 — Large-Scale physical containment level as described by the National Institutes of Health Guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Centers for Disease Control and National Institutes of Health. May 1988. Biosafety in Microbiological and Biomedical Laboratories. p. 97.

  2. Geoghegan, R.F. Jr and H.W. Meslar. April 1992. Interphex Seminar WS-1 Biocontainment.

  3. Giorgio, R.J. and J.J. Wu. March 1986. Design of Large Scale Containment Facilities For Recombinant DNA fermentations. TIBTech. pp. 60–65.

  4. Hill, D. and M. Beatrice. October 1989. Biotechnology Facility Requirements, Part 1 — Facility and Systems Design. BioPharm. pp. 20–26.

  5. Kearns, M.J. July/August 1989. Containment of Biological Hazards: Effect of Guidelines on the Design of Pharmaceutical Facilities and Process Equipment. Pharmaceutical Engineering. Vol. 9, No. 4, pp. 17–21.

    Google Scholar 

  6. National Institutes of Health. May 7, 1986. Guidelines for Research Involving Recombinant DNA Molecules; Notice. Federal Register Part III, Vol. 51, No. 88, pp. 16958–16985.

    Google Scholar 

  7. National Institutes of Health. July 18, 1991. Recombinant DNA Research: Actions Under the Guidelines; Notice. Federal Register Part III, Vol. 56, No. 138, pp. 33174–33183.

    Google Scholar 

  8. Organization for Economic Co-operation and Development. 1986. Recombinant DNA Safety Considerations. pp. 32–36., 53–55.

  9. Sekhar, C. April 29, 1985. Guidelines For Large-scale r-DNA Fermentations. Chemical Engineering. pp. 57–59.

  10. Tan, J. Z., R. F. Geoghegan, Jr. and T. C. Tyson. 1989. Liquid Waste Decontamination System in Biomedical and Pharmaceutical Facilities. Bioprocess Engineering Symposium, American Society of Mechanical Engineers.

  11. Tyler, J.E. March/April 1987. Recombinant DNA Fermentation Pilot Plant Design. Pharmaceutical Engineering. Vol. 7, No. 2, pp. 19–25.

    Google Scholar 

  12. Van Houten, J., D.O. Fleming, H.W. Meslar, and A.R. Moreira. August 1992. Controlling Biotechnology Risks: A Holistic Approach to Safety and Environmental Protection. Society for Industrial Microbiology Workshop II.

  13. World Health Organization. 1983. Laboratory Biosafety Manual. WHO Publications Centre, USA. pp. 11–12, 26–27, 29.

    Google Scholar 

  14. Van Houten, J. and D.O. Fleming. 1993. Comparative analysis of current US and EC biosafety regulations and their impact on the industry. J. Indust. Microbiol. 11: 209–215.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SmithKline Beecham Pharmaceuticals, P.O. Box 1539, 19406, King of Prussia, PA, USA

    Steven R. Miller & Don Bergmann

Authors
  1. Steven R. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Don Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, S.R., Bergmann, D. Biocontainment design considerations for biopharmaceutical facilities. Journal of Industrial Microbiology 11, 223–234 (1993). https://doi.org/10.1007/BF01569595

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01569595

Key words

Search

Navigation